The a2 Milk Company has cleared its final regulatory hurdle in China, securing approval to transition acquired infant formula registrations to its own brand while positioning the board to declare a substantial NZ$300 million fully franked special dividend.
Shares in The a2 Milk Company (ASX:A2M) advanced 0.89% to close at A$6.77, after spiking to an intraday high of A$7.20 out of the gate this morning. The opening surge reflected immediate market enthusiasm for the China regulatory clearance, though the pullback into the close suggests traders took profits after the initial reaction. The stock has now retraced from its early session peak but remains firmly above recent trading ranges, with the NZ$300 million special dividend implying an approximate 5% yield at current prices.
The Approval Driving The Move
China’s State Administration for Market Regulation (SAMR) has approved the transition of two China-label infant milk formula product registrations acquired through the a2 Pokeno facility purchase, allowing them to be marketed under the a2 Milk brand. This represents the final regulatory step required to fully execute the Pokeno acquisition structure, which was designed to secure vertical manufacturing capabilities and direct access to the heavily regulated Chinese market.
Under the terms of the original transaction, receipt of SAMR approval also removes a2 Milk’s contractual right to unwind the acquisition. The deal is now locked in on a permanent basis, committing the company’s capital and strategic direction to the New Zealand manufacturing footprint and China market access strategy that management has positioned as central to long-term growth.
The Pokeno facility acquisition is explicitly structured around “vertical manufacturing margin capture,” shifting production from third-party tolling arrangements to in-house manufacturing for both existing English-label products and new China-label SKUs. Management expects this transition to support gross margin expansion over time, though the facility requires ongoing capital expenditure, ERP implementation, and additional staffing through the FY26–FY28 period.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
Special Dividend
With the regulatory approvals secured, the a2 Milk board is expected to convene shortly to formally declare the flagged NZ$300 million special dividend. The payout will be fully franked and unimputed, providing a tangible near-term cash return that signals management confidence in the balance sheet and the view that excess capital is surplus to operational and growth requirements.
The special dividend comes on top of the company’s resumed ordinary dividend programme, which has been progressively increased as earnings recovered from the sharp downgrades experienced during 2020–2021. The capital return framework reinforces the narrative that a2 Milk has completed a structural reset, moving from a period of channel disruption and regulatory uncertainty to one characterised by stable cash generation and shareholder-friendly capital allocation.
The decision to return capital rather than pursue further acquisitions or aggressive share buybacks suggests management sees limited opportunities to deploy cash at sufficiently attractive returns in the near term, while also recognising that income-focused investors have been underserved during the company’s turnaround phase.
Structural Challenges Remain
While the regulatory approval and special dividend are clear positives, a2 Milk continues to face structural headwinds in its core China infant formula category. Birth rates in China have declined materially in recent years, compressing the addressable market for infant nutrition products. Competition from both domestic Chinese brands and other international players remains intense, with local manufacturers often benefiting from regulatory preferences and lower cost structures.
The company has also been explicit in recent communications that operational risks persist around the Pokeno integration, product transitions, and distribution strategies in China amid shifting channel dynamics. Foreign exchange volatility adds another layer of complexity, with movements in the NZD/AUD versus the renminbi and US dollar capable of materially swinging reported results even when underlying demand remains stable.
The SAMR approval and special dividend position a2 Milk to capitalise on its China strategy while rewarding shareholders for the turnaround journey. The company now controls a vertically integrated manufacturing platform with direct access to the China-label infant formula channel, supporting both margin expansion and product innovation tailored to the world’s largest infant nutrition market.
The early session spike to A$7.20 followed by a fade suggests markets are positive but not euphoric, pricing in the good news while maintaining a degree of scepticism about whether the China recovery can be sustained and whether Pokeno will deliver on its ambitious financial targets.
